DNAnexus Blog - Product updates, industry insights, opinions and references. From the team powering the Genomics Revolution.

Taking DNAnexus to the next level - Inside DNAnexus

Written by Andreas Sundquist | Oct 12, 2011 11:35:05 PM

Today we’re proud to announce the addition of two partners to DNAnexus: Google Ventures and TPG Biotech, the best big data investor and the best life sciences investor. Together with previous investors First Round Capital, SoftTech VC, K9 Ventures, and Felicis VC, we’ve raised $15 million in capital in this round to continue building our company and vision for the genomics revolution.

We also welcome the addition of two individuals to our board: Geoff Duyk, partner and managing director at TPG Biotech, and Krishna Yeshwant, partner at Google Ventures, whose insight and experience we value deeply. We consider Google Ventures and TPG Biotech to be extensions of our team, providing unrivaled industry reach and access to top technical expertise and infrastructure.

How will this affect the company? For starters, we’ve moved our headquarters to Mountain View and grown the company substantially, and continue to recruit the absolute best individuals to build our team. A big emphasis is on identifying the best software engineers and computer scientists, people who appreciate working on complex, big data problems, and want to make a meaningful impact on the world. Intrigued? Know someone who might be a fit? Take a look at our openings, or refer someone you know for a unique referral bonus.

Next, we’re investing in a number of efforts with the goal to bring together data and tools to allow the medical and biotech communities to extract meaning from sequencing data. One such effort is being announced today: a commitment to continue providing access to one of the most comprehensive archives of publicly available sequence data: the Sequence Read Archive. You can read more in the blog post below.

Congratulations to the DNAnexus team and everyone involved. We see this as a huge opportunity to pursue our mission: to unlock the potential of DNA-based medicine and biotechnology by creating scalable and collaborative data technologies.